archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Half-year results announcement for 2011/12
    17 million or 3 on a reported basis when compared to the prior comparable period This result included an unfavourable foreign exchange impact of 95 million On a constant currency 1 basis net profit after tax grew 16 Earnings per share benefited from current and past capital management initiatives Download this release CSL Half Year Results Announcement for 2011 12 0 08 Mb Additional resources The Webcast Analyst presentation and

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255928307673/prdetail.htm (2014-01-05)
    Open archived version from archive


  • Research Practices
    monitoring program to ensure adherence to the SOPs and drive inspection readiness A well defined Corrective Action Preventive Action CAPA management process that promotes a systematic approach to dealing with critical major issues and enabling study teams to effectively apply real time lessons learned Execution of audits on our investigative sites vendors and internal processes systems Informed consent Participation in clinical trials is voluntary and people cannot take part in a clinical trial without their knowledge and consent CSL conducts clinical research under strict procedures of informed consent Informed consent is a process of information exchange that involves providing a subject with the key information about a study and ensuring that the subject understands what the study is about This information exchange occurs before a subject decides to enrol in a study and the exchange continues for the duration of the study should the subject decide to take part Information about the study is provided in language that is easy to understand and includes the aim of the study what will happen during the study what the researchers are hoping to accomplish the treatments being tested and how they are thought to work and any potential risks and benefits to the subject Informed consent protects participants from unauthorised research and protects participants rights and privacy Participants can withdraw from a CSL clinical trial at any time CSL performs rigorous monitoring at investigative sites for all clinical trials to ensure every single participant has freely given documented informed consent prior to participation Furthermore CSL informed consent procedures ensure updates when there are changes to the study new information on risks to the form are applied in a timely manner and communicated to the participant as soon as possible in order that they can make an educated decision to continue on in the clinical trial Clinical trial transparency CSL is committed to ensuring the transparency and public accessibility of information related to our global clinical research activities We register our CSL sponsored clinical trials on a public registry before trial initiation to help patients their healthcare providers and caregivers identify clinical trials that might be appropriate for them Observational and or non interventional trials are also registered as required by applicable regulations We disclose the results of these trials in a timely fashion according to regulatory and legal requirements regardless of outcome on a publicly available results database to ensure that patients healthcare providers caregivers and patient advocacy groups have ready access to trial results The primary trial registry and results database used by CSL is ClinicalTrials gov which is administered by the United States National Library of Medicine CSL may also register clinical trials and disclose results on other trial registries and databases in compliance with local applicable regulatory and legal requirements In general we also seek to publish the results of our sponsored clinical trials in peer reviewed journals CSL follows a documented process for trial registration and results disclosure which reflects the CSL company policy on disclosure We keep

    Original URL path: http://www.csl.com.au/corporate-responsibility/research-practices.htm (2014-01-05)
    Open archived version from archive

  • CSL Support of Australian Patient Groups
    impacted by lung disease Multiple Sclerosis Australia A restricted contribution of fixed value to support education and training programs undertaken by Multiple Sclerosis Australia Pain Australia An unrestricted grant to support pain education awareness and advocacy activities relating to Pain Australia s objectives The Inflammatory Neuropathy Support Group of Victoria Inc An unrestricted educational grant of fixed value to support the continued registration and maintenance of an Inflammatory Neuropathy Support Group website to enhance access to patient support materials CSL Support in 2012 In the period January to December 2012 CSL supported the following Australian patient groups Cancer Council Victoria A donation equivalent to employee contributions made to the Cancer Council through CSL s workplace giving program to support the Cancer Council Victoria HAE Australia Unrestricted donation of fixed value to support educational activities undertaken by HAE according to HAE objectives Haemophilia Foundation Australia Unrestricted donation to support education advocacy and research activities undertaken by HFA according to HFA objectives Heart Foundation An unrestricted donation equivalent to employee contributions received by the Heart Foundation through CSL s workplace giving program Immune Deficiency Foundation of Australia An unrestricted educational grant of fixed value to support the production of education materials for people with primary immune deficiency MS Research Australia An unrestricted donation of fixed value to support research activities coordinated by MS Research Australia An unrestricted donation of fixed value to support education and awareness through MS Research Australia s Kiss Goodbye to MS campaign The MS Society of South Australia and Northern Territory Sponsorship of a key note address at an MS Society patient gathering The Myositis Association An unrestricted educational grant to support primary activities of patient education and support Pain Australia An unrestricted grant to support pain education awareness and advocacy activities relating to Pain Australia s objectives The Inflammatory Neuropathy Support Group of Victoria Inc An unrestricted educational grant of fixed value to support the development and registration of the Inflammatory Neuropathy Support Group website to enhance access to patient support materials CSL Support in 2011 In the period January to December 2011 CSL supported the following Australian patient groups Australian Federation of AIDS Organisations An unrestricted educational grant to assist in the development of educational resources to increase awareness of and health literacy regarding human papillomavirus HPV disease burden in males Cancer Council Victoria A donation equivalent to employee contributions made to the Cancer Council through CSL s workplace giving program to support the Cancer Council s Helpline Service Haemophilia Foundation Australia HFA Sponsorship of the HFA s biennial conference the 16th Australian New Zealand Haemophilia Conference to be held in October 2011 An unrestricted donation of fixed value to support education advocacy and research activities undertaken by HFA according to HFA objectives Heart Foundation An unrestricted donation equivalent to employee contributions received by the Heart Foundation through CSL s workplace giving program Sponsorship of the Heart Foundation Pharmaceutical Roundtable to support research and the quality use of cardiovascular medicines Pain Australia An unrestricted grant to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924873738/content/1255924873702/content.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    19 10 2011 CSL announces A 900m share buy back CSL Limited today announced a new on market buy back of up to A 900 million of CSL shares More 29 09 2011 CSL Biotherapies Response to News Reports on FDA Inspections CSL Biotherapies wishes to clarify that it has not received any new letters or warnings from the US Food and Drug Authority FDA or the Australian Therapeutic Goods Administration TGA concerning its compliance with current Good Manufacturing Practice cGMP More 27 09 2011 CSL Biotherapies Restricted Supply of BenPen CSL Biotherapies has advised hospitals that BenPen Benzylpenicillin is on restricted supply in Australia and New Zealand until December 2011 More 06 09 2011 CSL opens 4 8m workplace childcare centre CSL Limited and the Early Childhood Management Services ECMS today proudly opened the Thinking Kids Children s Centre an early childhood education and care centre at CSL s Parkville site in Victoria More 17 08 2011 Full Year Results Announcement for 2010 11 CSL Limited today reported a net profit after tax of 941 million for the twelve months ended 30 June 2011 down 112 million or 11 when compared to the prior comparable period More 17 08 2011 CSL Announces Changes to the Board CSL Limited ASX CSL today announced that Chairman Miss Elizabeth Alexander AM and Director Mr David Simpson have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 19 October 2011 More 18 07 2011 CSL Subsidiary Donates von Willebrand Factor Factor VIII to World Federation of Hemophilia CSL Behring gives more than 1 million units of VWD medication via WFH s Global Alliance for Progress program as part of its 3 year commitment to the organization More 22 06 2011

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1255929883418/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Reduction of Panvax Junior Ongoing monitoring by both CSL and the TGA of CSL s Panvax Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported Panvax Junior is the paediatric presentation of CSL s 2009 H1N1 pandemic influenza vaccine which is supplied in a single 0 25ml pre filled syringe More 30 07 2010 Update on Seasonal Influenza Vaccination of Children CSL Limited CSL supports the statement made today by the Commonwealth Chief Medical Officer regarding seasonal flu vaccine for young children More 15 07 2010 CSL Announces New Biotech Facility CSL Limited today announced a major biotechnology project at CSL s manufacturing site in Broadmeadows Australia The centrepiece of the project will be the creation of Victoria s first large scale biotechnology facility for the late stage development of new therapies for cancer bleeding disorders inflammation and infection More 01 06 2010 Update on Seasonal Influenza Vaccination of Young Children CSL Biotherapies CSL today notes the Chief Medical Officer s statement and updated recommendations regarding influenza vaccination for children under 5 More 23 04 2010 Seasonal influenza vaccine paediatric adverse events CSL Biotherapies is aware

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1255926256247/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    leading biopharmaceutical company has today announced that it is donating 3 million doses of pandemic H1N1 2009 or swine flu vaccine to the World Health Organisation for use in priority low income countries in the South Pacific as well as South East Asia More 06 10 2009 Vaccines delivered on time across Australia for largest national immunisation program on record CSL Biotherapies a subsidiary of CSL Australia s leading biopharmaceutical company can today confirm that 100 of deliveries of its H1N1 influenza vaccine are being completed on time in all States More 18 09 2009 Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration CSL Biotherapies a subsidiary of CSL Limited Australia s leading biopharmaceutical company can today confirm that its vaccine against the pandemic H1N1 2009 influenza or swine flu has been approved registration for use in people aged 10 years and over The TGA assesses safety efficacy and quality when arriving at the decision to register a medical product for use by the general public More 11 09 2009 CSL demonstrates robust immune response from single 15mcg dose of monovalent pandemic H1N1 2009 influenza A vaccine in healthy adults CSL Limited Australia s leading biopharmaceutical company announced today that preliminary data from the first study of its candidate pandemic H1N1 vaccine demonstrated a robust immune response in healthy adults after a single unadjuvanted 15mcg dose More 15 07 2009 CSL Backs Key Training Program for Health and Medical Sciences The Bio21 Cluster today announced sponsorship of its flagship education and training program by CSL Limited The sponsorship deal will underpin delivery of the Undergraduate Research Opportunities Program UROP for the next 3 years More 29 06 2009 Trial of Novel H1N1 Swine Flu candidate vaccine to take place in Adelaide CSL Limited Australia s leading biopharmaceutical company will shortly be commencing a clinical trial of a candidate vaccine against Novel H1N1 Swine Flu The trial will be undertaken in partnership with Clinical Research Organisation CMAX and the Royal Adelaide Hospital in South Australia More 09 06 2009 CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement CSL Limited ASX CSL and Talecris Biotherapeutics Inc announced today that they have mutually agreed to terminate their merger agreement announced on August 12 2008 under which CSL agreed to acquire Talecris for US 3 1 billion in cash More 09 06 2009 CSL announces on market share buyback CSL Limited ASX CSL today announced its intention to conduct an on market share buyback of up to 54 863 000 shares 1 This represents approximately 9 of the company s current shares on issue At an assumed price per share of approximately A 29 being CSL s last closing price on Friday 5 June this would represent a total buy back consideration of up to A 1 59 billion More 29 05 2009 CSL reaffirms its commitment to supply Australia with Novel Influenza A H1N1 Swine Flu Vaccine CSL Biotherapies a subsidiary of CSL Limited Australia s leading

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1255925765525/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    s first entry into the U S influenza vaccine market More 14 09 2007 Proposed 3 for 1 Share Split As previously announced CSL Limited is proposing to subdivide its issued capital on the basis that every one 1 fully paid ordinary share each a Share be subdivided into three 3 fully paid ordinary shares the Share Split and that options and performance rights on issue be adjusted in accordance with the Listing Rules More 22 08 2007 Full Year Results for 2007 CSL Limited today announced its operating result for the full year ended 30 June 2007 More 17 08 2007 Uptake of Free Cervical Cancer Vaccines Exceeds Expectations Uptake of Australia s cervical cancer vaccine through the National Immunisation Program in secondary schools has been highly successful CSL Limited said today Amongst the eligible school based population vaccine distribution and usage is running at levels not previously achieved in other vaccination programs in this age group In some states the uptake rate has been as high as 80 90 CSL has confirmed that in spite of the greater than expected demand it is able to supply the full needs of the program without difficulty More 13 04 2007 CSL Half Year Financial Report 2006 07 Strong profit growth in the first half of the year reflected a solid trading performance by CSL Behring through increased sales and better operating margins More 27 03 2007 CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug CSL 111 to acutely raise HDL good cholesterol levels may reduce the amount of plaque in the coronary arteries of patients with a recent episode of

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1199979016419/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Practitioners In total over 1 million Australian women and girls will be covered by the program More 09 11 2006 CSL announces acquisition of CytoGam from MedImmune Melbourne Australia CSL Limited has announced that its subsidiary ZLB Behring has reached an agreement with MedImmune Inc to acquire CytoGam cytomegalovirus immune globulin intravenous human and related assets CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus CMV which is indicated for prophylaxis against CMV disease associated with transplantation of the kidney lung liver pancreas and heart CMV is the most common cause of infection occurring after any solid organ transplant contributing significantly to morbidity and mortality in organ transplant recipients More 08 11 2006 Cervical cancer vaccination funding for Australian girls rejected CSL Limited Australia s leading biopharmaceutical company today announced that at last week s meeting the Pharmaceutical Benefits Advisory Committee PBAC rejected CSL s funding application for its cervical cancer vaccine GARDASIL CSL Limited Australia s leading biopharmaceutical company today announced that at last week s meeting the Pharmaceutical Benefits Advisory Committee PBAC rejected CSL s funding application for its cervical cancer vaccine GARDASIL More 01 09 2006 CSL Appoints New Director CSL today announced that Mr David Simpson has been appointed a Director of the Company effective from 1 September 2006 More 23 08 2006 CSL Full year Result Announcement for 2006 CSL Limited today announced its operating result for the full year ended 30 June 2006 More 23 08 2006 Iconic Australian Company Adopts New Look as a Global Organisation CSL Limited Australia s leading biopharmaceutical company today announced an updated look with a new logo to bring together its Australian and offshore group of companies together as a single global entity More 17 07 2006 CSL Announces Signing of a Merger Implementation Deed to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/page/1196562649797/PressReleaseArchive.htm (2014-01-05)
    Open archived version from archive